Key result
Type 1 poliovirus seroprevalence exceeds ~96% across all ages, but types 2 and 3 lag in infants.
Why the study?
Despite intensified use of monovalent oral poliovirus type 1 vaccine and improved immunization coverage, wild poliovirus type 1 persisted in Uttar Pradesh and Bihar from 2006 to 2009.
Cross-Sectional (n=950)
Yes
BACKGROUND: Despite intensified use of monovalent oral poliovirus type 1 vaccine and improved coverage of immunization campaigns, wild poliovirus type 1 persisted in Indian states of Uttar Pradesh and Bihar during 2006 to 2009. METHODS: A serosurvey was conducted among cases of acute flaccid paralysis in the 25 high-polio-incidence districts of western Uttar Pradesh. Children were recruited by age group (6-11 months, 12-24 months, and 25-69 months) from among cases reported through the acute flaccid paralysis surveillance system between November 2008 and August 2009. RESULTS: Seroprevalence for type 1 wild poliovirus was >96.4% for each age group. The seroprevalence of wild poliovirus types 2 and 3 increased with age, from 36.7% to 73.4% for type 2 and from 39.0% to 74.1% for type 3. In addition to the number of type-specific vaccine doses, father's level of education, being from a Muslim family, height for age, and female sex were the socioeconomic risk factors associated with seronegativity to poliovirus. CONCLUSIONS: The seroprevalence and risk factors identified in this study were consistent with the epidemiology of polio, and the findings were instrumental in optimizing vaccination strategy in western Uttar Pradesh with respect to the choice of OPV types, the frequency of supplementary immunization campaigns, and the urgency to improve routine immunization services.
No takes yet. Share an insight, caveat, or question.
Bahl et al. (2014) conducted a cross-sectional in Polio immunity / Acute flaccid paralysis (n=950). Oral poliovirus vaccination (OPV) was evaluated on Seroprevalence of antibodies to wild poliovirus types 1, 2, and 3. Seroprevalence for wild poliovirus type 1 exceeded 96.4% across all age groups, whereas immunity to types 2 and 3 was significantly lower in young infants and increased with age.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: